Photocure Partners with ISC for AI-Enhanced Bladder Cancer Detection

Barchart · 10/16/2025 11:46

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An announcement from Photocure ASA ( (PHCUF) ) is now available.

Photocure ASA has partnered with Intelligent Scopes Corporation to develop AI software integrated with blue light cystoscopy for improved bladder cancer detection. This collaboration aims to enhance early-stage detection and diagnosis, potentially transforming bladder cancer management and improving patient care by leveraging AI technology for more precise diagnostics.

More about Photocure ASA

Photocure ASA, known as The Bladder Cancer Company, is a leader in bladder cancer diagnostics, offering transformative solutions to improve patient outcomes. Its flagship products, Hexvix®/Cysview®, enhance bladder cancer detection through blue light cystoscopy. The company is headquartered in Oslo, Norway, and is publicly traded on the Oslo Stock Exchange.

Average Trading Volume: 52,514

Current Market Cap: NOK1.47B

Find detailed analytics on PHCUF stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.